...
首页> 外文期刊>Open Journal of Dentistry and Oral Medicine >Oral Corticosteroid Therapy for Preventing Postherpetic Neuralgia: A Systematic Review and Meta-analysis
【24h】

Oral Corticosteroid Therapy for Preventing Postherpetic Neuralgia: A Systematic Review and Meta-analysis

机译:口服皮质类固醇激素疗法预防带状疱疹后神经痛的系统评价和荟萃分析

获取原文
           

摘要

The purpose of this systematic review was to examine the efficacy of oral corticosteroids for prevention of postherpetic neuralgia (PHN). Randomized controlled trials of patients suffering from herpes zoster comparing corticosteroids to control therapy (placebo or carbamazepine) or acyclovir were included. Three electronic databases (MEDLINE via PubMed, Web of Science and The Cochrane Library) were searched. Two authors assessed all eligible studies for risk of bias. Ninety-one references were found. After applying inclusion/exclusion criteria 7 studies were eligible for this systematic review. All 7 studies were at high risk of bias. Corticosteroids, rather than carbamazepine, protected the patients against PHN (Relative Risk [RR] = 0.543, 95% CI 0.087 to 3.376, p=0.512), however the results were not statistically significant. Additionally, a second meta-analysis showed that the use of corticosteroids does not prevent PHN compared to the use of a placebo (RR=0.990, 95% CI 0.092 to 10.663, p=0.994). Mild and reversible side effects were reported in patients taking only corticosteroids; two serious cardiovascular events were reported in the patients prescribed acyclovir and corticosteroid, though those two events were probably unrelated to the therapy. Individual studies reported quality of life improvements and reduction in the incidence and severity of pain with the addition of prednisone to acyclovir therapy; however the heterogeneity of the outcomes and comparison group prevented from performing meta-analyses on these outcomes. Due to the low number of studies, high risk of bias, heterogeneity of the outcomes and comparison groups, the evidence this systematic review provided was of low quality.
机译:该系统评价的目的是检查口服皮质类固醇激素预防带状疱疹后神经痛(PHN)的功效。包括对带状疱疹患者比较皮质类固醇与对照疗法(安慰剂或卡马西平)或阿昔洛韦的随机对照试验。搜索了三个电子数据库(通过PubMed的MEDLINE,Web of Science和Cochrane图书馆)。两位作者评估了所有符合条件的研究的偏倚风险。找到了91个参考文献。应用纳入/排除标准后,有7项研究符合该系统评价的条件。所有7项研究都有偏见的高风险。皮质类固醇而非卡马西平可保护患者免受PHN的侵袭(相对危险度[RR] = 0.543,95%CI 0.087至3.376,p = 0.512),但结果无统计学意义。此外,第二项荟萃分析显示,与使用安慰剂相比,使用皮质类固醇不能预防PHN(RR = 0.990,95%CI 0.092至10.663,p = 0.994)。据报道,仅服用皮质类固醇的患者出现轻度和可逆的副作用。服用阿昔洛韦和皮质类固醇的患者中报告了两次严重的心血管事件,尽管这两个事件可能与治疗无关。个别研究报告说,在阿昔洛韦治疗中加入泼尼松可以改善生活质量,并减少疼痛的发生率和严重程度。然而,结果和比较组的异质性阻碍了对这些结果进行荟萃分析。由于研究数量少,偏见风险高,结果与对照组之间存在异质性,因此本系统评价提供的证据质量较低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号